## Brian F Gage

# List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/10240124/brian-f-gage-publications-by-year.pdf

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

14,626 48 130 120 h-index g-index citations papers 16,295 6.13 138 7.2 L-index avg, IF ext. papers ext. citations

#	Paper	IF	Citations
130	Improving Follow-up Attendance for Discharged Emergency Care Patients Using Automated Phone System to Self-schedule: A Randomized Controlled Trial. <i>Academic Emergency Medicine</i> , <b>2021</b> , 28, 197-7	203 <sup>4</sup>	O
129	Predictors of long-term opioid use and opioid use disorder among construction workers: Analysis of claims data. <i>American Journal of Industrial Medicine</i> , <b>2021</b> , 64, 48-57	2.7	4
128	Venous thromboembolism in multiple myeloma is associated with increased mortality. <i>Research and Practice in Thrombosis and Haemostasis</i> , <b>2020</b> , 4, 1203-1210	5.1	3
127	Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index. <i>Journal of Visualized Experiments</i> , <b>2020</b> ,	1.6	2
126	Maximal dose-response of vitamin-K2 (menaquinone-4) on undercarboxylated osteocalcin in women with osteoporosis. <i>International Journal for Vitamin and Nutrition Research</i> , <b>2020</b> , 90, 42-48	1.7	6
125	Splanchnic vein thrombosis predicts worse survival in patients with advanced pancreatic cancer. <i>Thrombosis Research</i> , <b>2020</b> , 185, 125-131	8.2	11
124	Statins Reduce Mortality in Multiple Myeloma: A Population-Based US Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2020</b> , 20, e937-e943	2	О
123	Lung transplant outcomes are influenced by severity of neutropenia and granulocyte colony-stimulating factor treatment. <i>American Journal of Transplantation</i> , <b>2020</b> , 20, 250-261	8.7	9
122	Effect of Low-Intensity vs Standard-Intensity Warfarin Prophylaxis on Venous Thromboembolism or Death Among Patients Undergoing Hip or Knee Arthroplasty: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2019</b> , 322, 834-842	27.4	5
121	Assessment of ICD-10-CM code assignment validity for case finding of outpatient anticoagulant-related bleeding among Medicare beneficiaries. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2019</b> , 28, 951-964	2.6	6
120	Predictive value of the present-on-admission indicator for hospital-associated hemorrhage. <i>Thrombosis Research</i> , <b>2019</b> , 180, 20-24	8.2	O
119	Reply: Coronary Artery Calcium Screening in the Young and Other Responses: The Walter Reed Cohort. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 73, 1873-1874	15.1	
118	Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score. <i>American Journal of Hematology</i> , <b>2019</b> , 94, 1176-1184	7.1	53
117	Derivation and Validation of a Risk Assessment Model for Immunomodulatory Drug-Associated Thrombosis Among Patients With Multiple Myeloma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2019</b> , 17, 840-847	7.3	46
116	The Association of Fever and Antipyretic Medication With Outcomes in Mechanically Ventilated Patients: A Cohort Study. <i>Shock</i> , <b>2019</b> , 52, 152-159	3.4	8
115	TEG Platelet Mapping and Impedance Aggregometry to Predict Platelet Transfusion During Cardiopulmonary Bypass in Pediatric Patients. <i>Frontiers in Pediatrics</i> , <b>2019</b> , 7, 509	3.4	5
114	Factors Associated With Clinical Deterioration Among Patients Hospitalized on the Wards at a Tertiary Cancer Hospital. <i>Journal of Oncology Practice</i> , <b>2019</b> , 15, e652-e665	3.1	9

### (2015-2018)

113	Postoperative Myocardial Injury and Inflammation Is Not Blunted by a Trial of Atorvastatin in Orthopedic Surgery Patients. <i>HSS Journal</i> , <b>2018</b> , 14, 67-76	2	2
112	Genotype vs Clinically Guided Dosing of Warfarin to Prevent Adverse Events-Reply. <i>JAMA - Journal of the American Medical Association</i> , <b>2018</b> , 319, 1279-1280	27.4	
111	Impact of Statins on Cardiovascular Outcomes Following Coronary Artery Calcium Scoring. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 72, 3233-3242	15.1	113
110	Improving Prediction of Postoperative Myocardial Infarction With High-Sensitivity Cardiac Troponin T and NT-proBNP. <i>Anesthesia and Analgesia</i> , <b>2017</b> , 124, 398-405	3.9	36
109	Reply to S. Suissa et al. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1378-1379	2.2	
108	The Reply. American Journal of Medicine, <b>2017</b> , 130, e115	2.4	
107	Effect of Genotype-Guided Warfarin Dosing on Clinical Events and Anticoagulation Control Among Patients Undergoing Hip or Knee Arthroplasty: The GIFT Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2017</b> , 318, 1115-1124	27.4	142
106	High-Sensitivity Cardiac Troponin T Improves the Diagnosis of Perioperative MI. <i>Anesthesia and Analgesia</i> , <b>2017</b> , 125, 1455-1462	3.9	15
105	Interview about the GIFT Trial, Pharmacogenetics, and Warfarin. <i>Pharmacogenomics</i> , <b>2017</b> , 18, 1379-13	<b>80</b> .6	1
104	Safety and Efficacy of New Anticoagulants for the Prevention of Venous Thromboembolism After Hip and Knee Arthroplasty: AlMeta-Analysis. <i>Journal of Arthroplasty</i> , <b>2017</b> , 32, 645-652	4.4	43
103	Statins Are Associated With Reduced Mortality in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 4008-4014	2.2	43
102	A systematic analysis and comparison of warfarin initiation strategies. <i>Pharmacogenetics and Genomics</i> , <b>2016</b> , 26, 445-52	1.9	5
101	A Tool to Assess Risk of De Novo Opioid Abuse or Dependence. <i>American Journal of Medicine</i> , <b>2016</b> , 129, 699-705.e4	2.4	43
100	Application of a Validated Predictive Model for Venous Thromboembolism in Cancer to Patients with Multiple Myeloma. <i>Blood</i> , <b>2016</b> , 128, 534-534	2.2	
99	Relationship Between Anticoagulation Intensity and Thrombotic or Bleeding Outcomes Among Outpatients With Continuous-Flow Left Ventricular Assist Devices. <i>Circulation: Heart Failure</i> , <b>2016</b> , 9,	7.6	65
98	Trends in antithrombotic therapy for atrial fibrillation: Data from the Veterans Health Administration Health System. <i>American Heart Journal</i> , <b>2016</b> , 179, 186-91	4.9	5
97	Accuracy of Wearable Cameras to Track Social Interactions in Stroke Survivors. <i>Journal of Stroke and Cerebrovascular Diseases</i> , <b>2016</b> , 25, 2907-2910	2.8	6
96	Effectiveness and safety of expanded perioperative thromboprophylaxis in complex gynecologic surgery. <i>Gynecologic Oncology</i> , <b>2015</b> , 138, 501-6	4.9	25

95	Prognostic utility of novel biomarkers of cardiovascular stress in patients with aortic stenosis undergoing valve replacement. <i>Heart</i> , <b>2015</b> , 101, 1382-8	5.1	68
94	Improving accuracy of International Classification of Diseases codes for venous thromboembolism in administrative data. <i>Thrombosis Research</i> , <b>2015</b> , 135, 616-20	8.2	49
93	Clinical Benefit of American College of Chest Physicians Versus European Society of Cardiology Guidelines for Stroke Prophylaxis in Atrial Fibrillation. <i>Journal of General Internal Medicine</i> , <b>2015</b> , 30, 1405	4	1
92	Risk model for estimating the 1-year risk of deferred lesion intervention following deferred revascularization after fractional flow reserve assessment. <i>European Heart Journal</i> , <b>2015</b> , 36, 509-15	9.5	27
91	Clinical outcomes with use of erythropoiesis stimulating agents in patients with the HeartMate II left ventricular assist device. <i>JACC: Heart Failure</i> , <b>2015</b> , 3, 146-53	7.9	19
90	Clinical Benefit of American College of Chest Physicians versus European Society of Cardiology Guidelines for Stroke Prophylaxis in Atrial Fibrillation. <i>Journal of General Internal Medicine</i> , <b>2015</b> , 30, 777-82	4	8
89	Metformin Therapy and Survival in Multiple Myeloma Among US Veterans with Diabetes Mellitus. <i>Blood</i> , <b>2015</b> , 126, 4502-4502	2.2	
88	Statin Therapy Improves Multiple Myeloma (MM) Specific Surviva. <i>Blood</i> , <b>2015</b> , 126, 879-879	2.2	
87	Incidence of Platelet Dysfunction by Thromboelastography-Platelet Mapping in Children Supported with ECMO: A Pilot Retrospective Study. <i>Frontiers in Pediatrics</i> , <b>2015</b> , 3, 116	3.4	38
86	Risk factors for inpatient venous thromboembolism despite thromboprophylaxis. <i>Thrombosis Research</i> , <b>2014</b> , 133, 25-9	8.2	34
85	In reply. <i>Anesthesiology</i> , <b>2014</b> , 120, 515-6	4.3	
84	Genotype and risk of major bleeding during warfarin treatment. <i>Pharmacogenomics</i> , <b>2014</b> , 15, 1973-83	2.6	45
83	Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients. <i>Thrombosis and Haemostasis</i> , <b>2014</b> , 111, 88-93	7	98
82	Letter in response to "Use of preoperative cardiac troponin T to identify patients at risk for acute myocardial infraction and long-term mortality after major noncardiac surgery". <i>American Heart Journal</i> , <b>2014</b> , 167, e7	4.9	
81	Venous Thromboembolism Is Associated with Increased Mortality in Patients with Multiple Myeloma. <i>Blood</i> , <b>2014</b> , 124, 2176-2176	2.2	1
80	A pharmacogenetic versus a clinical algorithm for warfarin dosing. <i>New England Journal of Medicine</i> , <b>2013</b> , 369, 2283-93	59.2	547
79	Rationale and design of the Clarification of Optimal Anticoagulation through Genetics trial. <i>American Heart Journal</i> , <b>2013</b> , 166, 435-41	4.9	13
78	The analysis of bleeding risk-prediction scores should include all major bleeds. <i>Journal of the American College of Cardiology</i> , <b>2013</b> , 61, 481-482	15.1	1

### (2010-2013)

77	Top practice-changing articles over the last two years. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2013</b> , 35, 325-32	5.1	
76	High-sensitivity cardiac troponin T in prediction and diagnosis of myocardial infarction and long-term mortality after noncardiac surgery. <i>American Heart Journal</i> , <b>2013</b> , 166, 325-332.e1	4.9	112
75	Influence of nitrous oxide anesthesia, B-vitamins, and MTHFR gene polymorphisms on perioperative cardiac events: the vitamins in nitrous oxide (VINO) randomized trial. <i>Anesthesiology</i> , <b>2013</b> , 119, 19-28	4.3	31
74	Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy. <i>Thrombosis and Haemostasis</i> , <b>2012</b> , 107, 232-40	7	56
73	Effects of phosphodiesterase type 5 inhibition on systemic and pulmonary hemodynamics and ventricular function in patients with severe symptomatic aortic stenosis. <i>Circulation</i> , <b>2012</b> , 125, 2353-62	16.7	47
7 <sup>2</sup>	Admission international normalized ratio levels, early treatment strategies, and major bleeding risk among non-ST-segment-elevation myocardial infarction patients on home warfarin therapy: insights from the National Cardiovascular Data Registry. <i>Circulation</i> , <b>2012</b> , 125, 1414-23	16.7	14
71	Risk Factors for Inpatient Acute Venous Thromboembolism (VTE) Despite Thromboprophylaxis <i>Blood</i> , <b>2012</b> , 120, 2248-2248	2.2	
70	Higher Doses of Prophylactic Anticoagulation Is More Effective in Preventing Venous Thromboembolism in Morbidly Obese Inpatients <i>Blood</i> , <b>2012</b> , 120, 2268-2268	2.2	
69	Genetic warfarin dosing: tables versus algorithms. <i>Journal of the American College of Cardiology</i> , <b>2011</b> , 57, 612-8	15.1	110
68	Physician and nurse acceptance of technicians to screen for geriatric syndromes in the emergency department. Western Journal of Emergency Medicine, 2011, 12, 489-95	3.3	42
67	Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. <i>Circulation</i> , <b>2011</b> , 123, 2562	<b>-76</b> .7	259
66	Gamma-glutamyl carboxylase and its influence on warfarin dose. <i>Thrombosis and Haemostasis</i> , <b>2010</b> , 104, 750-4	7	46
65	Cost-effectiveness of outpatient cardiac monitoring to detect atrial fibrillation after ischemic stroke. <i>Stroke</i> , <b>2010</b> , 41, 1514-20	6.7	67
64	Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). <i>Journal of the American College of Cardiology</i> , <b>2010</b> , 55, 2804-12	15.1	279
63	Pediatric warfarin practice and pharmacogenetic testing. <i>Thrombosis Research</i> , <b>2010</b> , 126, e144-6	8.2	9
62	Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. <i>Blood</i> , <b>2010</b> , 115, 3827-34	2.2	289
61	Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial. <i>Trials</i> , <b>2010</b> , 11, 108	2.8	72
60	Validation of claims-based diagnostic and procedure codes for cardiovascular and gastrointestinal serious adverse events in a commercially-insured population. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2010</b> , 19, 596-603	2.6	120

59	Can we rely on RE-LY?. New England Journal of Medicine, 2009, 361, 1200-2	59.2	56
58	Interactive modeling for ongoing utility of pharmacogenetic diagnostic testing: application for warfarin therapy. <i>Clinical Chemistry</i> , <b>2009</b> , 55, 1861-8	5.5	38
57	Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score. <i>Circulation</i> , <b>2009</b> , 119, 1873-82	16.7	701
56	Anemia: an independent predictor of death and hospitalizations among elderly patients with atrial fibrillation. <i>American Heart Journal</i> , <b>2009</b> , 157, 1057-63	4.9	24
55	Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. <i>Annals of Internal Medicine</i> , <b>2009</b> , 150, 73-83	8	217
54	Couma-Gen: implications for future randomized trials of pharmacogenetic-based warfarin therapy. <i>Personalized Medicine</i> , <b>2008</b> , 5, 163-168	2.2	3
53	Performance of commercial platforms for rapid genotyping of polymorphisms affecting warfarin dose. <i>American Journal of Clinical Pathology</i> , <b>2008</b> , 129, 876-83	1.9	63
52	CYP4F2 genetic variant alters required warfarin dose. <i>Blood</i> , <b>2008</b> , 111, 4106-12	2.2	428
51	Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2008</b> , 25, 45-51	5.1	186
50	Can patients at elevated risk of stroke treated with anticoagulants be further risk stratified?. <i>Stroke</i> , <b>2007</b> , 38, 2459-63	6.7	59
49	Anemia does not predict mortality in elderly patients with heart failure. <i>The American Journal of Geriatric Cardiology</i> , <b>2007</b> , 16, 92-6		8
48	An invasive strategy is associated with decreased mortality in patients 80 years and older with acute myocardial infarction. <i>The American Journal of Geriatric Cardiology</i> , <b>2007</b> , 16, 84-91		2
47	Optimal initial dose adjustment of warfarin in orthopedic patients. <i>Annals of Pharmacotherapy</i> , <b>2007</b> , 41, 1798-804	2.9	23
46	Genetic-based dosing in orthopedic patients beginning warfarin therapy. <i>Blood</i> , <b>2007</b> , 110, 1511-5	2.2	152
45	Is primary care ready for pharmacogenetics?. <i>Pharmacogenomics</i> , <b>2006</b> , 7, 1-3	2.6	6
44	Pharmacogenetics-based coumarin therapy. <i>Hematology American Society of Hematology Education Program</i> , <b>2006</b> , 2006, 467-73	3.1	48
43	Risk of osteoporotic fracture in elderly patients taking warfarin: results from the National Registry of Atrial Fibrillation 2. <i>Archives of Internal Medicine</i> , <b>2006</b> , 166, 241-6		162
42	The Association of Warfarin Use With Osteoporotic Fracture in Elderly Patients With Atrial Fibrillation Reply. <i>Archives of Internal Medicine</i> , <b>2006</b> , 166, 1525		

41	Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation. <i>Stroke</i> , <b>2006</b> , 37, 10	70 <i>6</i> 47	235
40	Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). <i>American Heart Journal</i> , <b>2006</b> , 151, 713-9	4.9	732
39	Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. <i>New England Journal of Medicine</i> , <b>2005</b> , 352, 2285-93	59.2	1149
38	Reliability for grading acute rejection and airway inflammation after lung transplantation. <i>Journal of Heart and Lung Transplantation</i> , <b>2005</b> , 24, 652-7	5.8	48
37	Pharmacology and pharmacogenetics of warfarin and other coumarins when used with supplements. <i>Thrombosis Research</i> , <b>2005</b> , 117, 55-9; discussion 65-7	8.2	14
36	Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. <i>American Journal of Medicine</i> , <b>2005</b> , 118, 612-7	2.4	244
35	Implantable cardioverter-defibrillator therapy improves long-term survival in patients with unexplained syncope, cardiomyopathy, and a negative electrophysiologic study. <i>Heart Rhythm</i> , <b>2005</b> , 2, 367-73	6.7	17
34	The pharmacogenetics of coumarin therapy. <i>Pharmacogenomics</i> , <b>2005</b> , 6, 503-13	2.6	78
33	Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors. <i>Medical Care</i> , <b>2005</b> , 43, 480-5	3.1	574
32	Comorbidity indices to predict mortality from Medicare data: results from the national registry of atrial fibrillation. <i>Medical Care</i> , <b>2005</b> , 43, 1073-7	3.1	60
31	Simplified peak power reserve in patients with an implantable cardioverter-defibrillator and advanced heart failure. <i>American Journal of Cardiology</i> , <b>2005</b> , 95, 286-8	3	
30	Use of EPO in critically ill patients with acute renal failure requiring renal replacement therapy. <i>American Journal of Kidney Diseases</i> , <b>2005</b> , 46, 791-8	7.4	22
29	Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. <i>Thrombosis and Haemostasis</i> , <b>2005</b> , 93, 700-5	7	163
28	Preference-based antithrombotic therapy in atrial fibrillation: implications for clinical decision making. <i>Medical Decision Making</i> , <b>2005</b> , 25, 548-59	2.5	57
27	Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. <i>JAMA - Journal of the American Medical Association</i> , <b>2005</b> , 293, 699-706	27.4	120
26	Effect of warfarin nonadherence on control of the International Normalized Ratio. <i>American Journal of Health-System Pharmacy</i> , <b>2004</b> , 61, 1258-64	2.2	65
25	Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. <i>Circulation</i> , <b>2004</b> , 110, 2287-92	16.7	616
24	Cost-effectiveness of extending Medicare coverage of immunosuppressive medications to the life of a kidney transplant. <i>American Journal of Transplantation</i> , <b>2004</b> , 4, 1703-8	8.7	77

23	Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. <i>Thrombosis and Haemostasis</i> , <b>2004</b> , 91, 87-94	7	282
22	The management of anticoagulants in the periendoscopic period for patients with atrial fibrillation: a decision analysis. <i>American Journal of Medicine</i> , <b>2004</b> , 116, 451-9	2.4	22
21	Yield of surveillance bronchoscopy for acute rejection and lymphocytic bronchitis/bronchiolitis after lung transplantation. <i>Journal of Heart and Lung Transplantation</i> , <b>2004</b> , 23, 1396-404	5.8	41
20	Use of pharmacogenetics to guide warfarin therapy. <i>Drugs of Today</i> , <b>2004</b> , 40, 247-57		6
19	Randomized trial of warfarin nomograms. Annals of Internal Medicine, 2004, 140, 489; author reply 491-	<b>2</b> 8	2
18	Warfarin dose reduction vs watchful waiting for mild elevations in the international normalized ratio. <i>Chest</i> , <b>2003</b> , 123, 499-503	5.3	27
17	Pharmacogenetics and anticoagulant therapy. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2003</b> , 16, 73-8	5.1	22
16	Outpatient treatment of acute venous thromboembolic disease. Clinics in Chest Medicine, 2003, 24, 49-0	<b>55</b> .3	9
15	Perioperative reduction of the warfarin dose. American Journal of Medicine, 2003, 115, 741-2	2.4	5
14	Predictors of mortality in younger and older patients with heart failure and preserved or reduced left ventricular ejection fraction. <i>American Heart Journal</i> , <b>2003</b> , 146, 286-90	4.9	53
13	Cost-savings analysis of using a portable coagulometer for monitoring homebound elderly patients taking warfarin. <i>The American Journal of Geriatric Cardiology</i> , <b>2003</b> , 12, 283-7		18
12	Substitution of generic warfarin for Coumadin in an HMO setting. <i>Annals of Pharmacotherapy</i> , <b>2002</b> , 36, 764-8	2.9	26
11	The impact of the introduction of a rapid D-dimer assay on the diagnostic evaluation of suspected pulmonary embolism. <i>Archives of Internal Medicine</i> , <b>2001</b> , 161, 567-71		48
10	Patient and physician satisfaction with a telephone-based anticoagulation service. <i>Journal of General Internal Medicine</i> , <b>2001</b> , 16, 460-3	4	37
9	Establishing and running an effective telephone-based anticoagulation service. <i>Journal of Vascular Nursing</i> , <b>2001</b> , 19, 126-32; quiz 133-4	1	16
8	Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. <i>JAMA - Journal of the American Medical Association</i> , <b>2001</b> , 285, 2864-70	27.4	3578
7	Seasonal control of warfarin therapy. American Journal of Medicine, 2001, 111, 332	2.4	1
6	Warfarin therapy for an octogenarian who has atrial fibrillation. <i>Annals of Internal Medicine</i> , <b>2001</b> , 134, 465-74	8	40

#### LIST OF PUBLICATIONS

5	Adverse outcomes and predictors of underuse of antithrombotic therapy in medicare beneficiaries with chronic atrial fibrillation. <i>Stroke</i> , <b>2000</b> , 31, 822-7	6.7	253
4	Management and dosing of warfarin therapy. American Journal of Medicine, 2000, 109, 481-8	2.4	123
3	Criteria for outpatient management of proximal lower extremity deep venous thrombosis. <i>Chest</i> , <b>1999</b> , 115, 972-9	5.3	34
2	Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation. <i>Stroke</i> , <b>1998</b> , 29, 1083-91	6.7	87
1	Cost-effectiveness of Warfarin and Aspirin for Prophylaxis of Stroke in Patients With Nonvalvular Atrial Fibrillation. <i>JAMA - Journal of the American Medical Association</i> , <b>1995</b> , 274, 1839	27.4	182